BORA PHARMACEUTICALS LTD (6472) — Cash Flow Quality Index
BORA PHARMACEUTICALS LTD (6472) has a Cash Flow Quality Index of 14.11x as of March 2026. Operating cash flow of NT$568.46 Million exceeds net income of NT$40.29 Million, indicating high earnings quality where cash backs reported profits. Explore how well can BORA PHARMACEUTICALS LTD service its debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BORA PHARMACEUTICALS LTD Cash Flow Quality Index (2019–2025)
Historical Cash Flow Quality Index for BORA PHARMACEUTICALS LTD across 7 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash efficiency ratio of BORA PHARMACEUTICALS LTD.
Annual Cash Flow Quality Index for BORA PHARMACEUTICALS LTD (2019–2025)
Year-by-year earnings quality comparison for BORA PHARMACEUTICALS LTD.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.42x | NT$4.24 Billion | NT$2.98 Billion | ▲ +618.8% |
| 2024 | 0.20x | NT$980.81 Million | NT$4.95 Billion | ▼ -82.6% |
| 2023 | 1.14x | NT$4.61 Billion | NT$4.06 Billion | ▲ +3.9% |
| 2022 | 1.09x | NT$2.01 Billion | NT$1.84 Billion | ▼ -9.5% |
| 2021 | 1.21x | NT$1.24 Billion | NT$1.02 Billion | ▲ +304.4% |
| 2020 | 0.30x | NT$177.79 Million | NT$595.40 Million | ▼ -60.7% |
| 2019 | 0.76x | NT$231.77 Million | NT$305.03 Million | — |